408 related articles for article (PubMed ID: 27075683)
1. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet.
Yang G; Lee HE; Lee JY
Sci Rep; 2016 Apr; 6():24399. PubMed ID: 27075683
[TBL] [Abstract][Full Text] [Related]
2. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
[TBL] [Abstract][Full Text] [Related]
3. Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation.
Yang G; Yeon SH; Lee HE; Kang HC; Cho YY; Lee HS; Lee JY
Rheumatology (Oxford); 2018 Apr; 57(4):727-736. PubMed ID: 29340626
[TBL] [Abstract][Full Text] [Related]
4. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
Sui YH; Luo WJ; Xu QY; Hua J
World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
Zhu W; Feng PP; He K; Li SW; Gong JP
Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
[TBL] [Abstract][Full Text] [Related]
6. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
[TBL] [Abstract][Full Text] [Related]
7. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
10. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.
Sun CC; Zhang CY; Duan JX; Guan XX; Yang HH; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX; Liu SK; Zhang J
Biochem Biophys Res Commun; 2020 Mar; 523(4):1020-1026. PubMed ID: 31973813
[TBL] [Abstract][Full Text] [Related]
11. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3.
Ruan S; Han C; Sheng Y; Wang J; Zhou X; Guan Q; Li W; Zhang C; Yang Y
Int Immunopharmacol; 2021 Nov; 100():108126. PubMed ID: 34492534
[TBL] [Abstract][Full Text] [Related]
12. The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation.
Wang X; Gao Y; Song J; Tang C; Wang M; Que L; Liu L; Zhu G; Chen Q; Yao Y; Xu Y; Li J; Li Y
Br J Pharmacol; 2017 Jun; 174(12):1841-1856. PubMed ID: 28306139
[TBL] [Abstract][Full Text] [Related]
13. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
[TBL] [Abstract][Full Text] [Related]
14. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
Liu J; Wang T; He K; Xu M; Gong JP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
[TBL] [Abstract][Full Text] [Related]
15. Silybin inhibits NLRP3 inflammasome assembly through the NAD
Zhang B; Xu D; She L; Wang Z; Yang N; Sun R; Zhang Y; Yan C; Wei Q; Aa J; Liu B; Wang G; Xie Y
FASEB J; 2018 Feb; 32(2):757-767. PubMed ID: 28970254
[TBL] [Abstract][Full Text] [Related]
16. Mangiferin Ameliorates HFD-Induced NAFLD through Regulation of the AMPK and NLRP3 Inflammasome Signal Pathways.
Yong Z; Ruiqi W; Hongji Y; Ning M; Chenzuo J; Yu Z; Zhixuan X; Qiang L; Qibing L; Weiying L; Xiaopo Z
J Immunol Res; 2021; 2021():4084566. PubMed ID: 34734090
[TBL] [Abstract][Full Text] [Related]
17. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways.
Lv Y; Gao X; Luo Y; Fan W; Shen T; Ding C; Yao M; Song S; Yan L
J Nutr Biochem; 2019 Sep; 71():110-121. PubMed ID: 31325892
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.
Dwivedi DK; Jena GB
Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):705-716. PubMed ID: 31834465
[TBL] [Abstract][Full Text] [Related]
20. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
